Results 41 to 50 of about 5,633 (170)

Ascorbic acid reduces the genetic damage caused by miltefosine (hexadecylphosphocholine) in animals infected by Leishmania (Leishamnia) infantum without decreasing its antileishmanial activity

International Journal for Parasitology: Drugs and Drug Resistance, 2019
Leishamaniasis is a neglected disease caused by over 20 Leishmania species, occurring in more than a hundred countries. Miltefosine (hexadecylphosphocholine) is the single oral drug used in treatment for leshmaniases, including cases of infections ...
Patrícia Valéria Castelo-Branco, Hugo José Alves, Raissa Lacerda Pontes, Vera Lucia Maciel-Silva, Silma Regina Ferreira Pereira   +4 more
doaj   +1 more source

Leishmania Extracellular Vesicles as a Preventive Vaccine Platform Against Leishmaniasis

Journal of Extracellular Vesicles, Volume 15, Issue 4, April 2026.
The potential of Leishmania‐derived extracellular vesicles (EVs) as a vaccine platform was investigated, emphasizing an affordable, GMP‐compliant production and purification method. Immunization with EV vaccines, either unadjuvanted or combined with α‐galactosylceramide (αGC), induced robust humoral and cellular immune responses, conferring protection ...
Ismail Cem Yilmaz, Ibrahim Tokmak, Muzaffer Yildirim, Tugce Canavar Yildirim, Elif Sena Ozkoc, Irem Evcili, Emre Mert Ipekoglu, İhsan Cihan Ayanoglu, Emre Dunuroglu, Dicle Caliskan, Harun Onler, Zeynep Arzum, Ceren Ulker, Olcay Mert, Ridvan Orkut, Ibrahim Oguzhan Tarman, Ulku Guler, Bekir Salih, Volkan Yazar, Gokcen Ozgun, Serap Birincioglu, Ahmet Ozbilgin, Bilgi Gungor, Ihsan Gursel, Mayda Gursel   +24 more
wiley   +1 more source

EVALUATION OF MILTEFOSINE AGAINST LEISHMANIA MAJOR (MRHO/IR/75/ER): IN VITRO AND IN VIVO STUDIES [PDF]

Acta Medica Iranica, 2008
Cutaneous leishmaniasis is endemic in 88 different countries. There are an estimated 1.5 million new cases each year, with over 90% occurring in Afghanistan, Algeria, Iran, Iraq, Saudi Arabia, Syria (Old World) and in Brazil and Peru (New World ...
J. Esmaeili, M. Mohebali, G. H. Edrissian, S. M. Rezayat, M. Ghazi-Khansari, S. Charehdar   +5 more
doaj   +2 more sources

A Leishmania infantum genetic marker associated with miltefosine treatment failure for visceral leishmaniasisResearch in context

EBioMedicine, 2018
Background: Miltefosine has been used successfully to treat visceral leishmaniasis (VL) in India, but it was unsuccessful for VL in a clinical trial in Brazil.
Juliana B.T. Carnielli, Kathryn Crouch, Sarah Forrester, Vladimir Costa Silva, Sílvio F.G. Carvalho, Jeziel D. Damasceno, Elaine Brown, Nicholas J. Dickens, Dorcas L. Costa, Carlos H.N. Costa, Reynaldo Dietze, Daniel C. Jeffares, Jeremy C. Mottram   +12 more
doaj   +1 more source

Translational Pharmacokinetic‐Pharmacodynamic Modeling and Efficacious Human Dose Prediction of DNDI‐6148 for the Treatment of Cutaneous Leishmaniasis

Clinical and Translational Science, Volume 19, Issue 4, April 2026.
ABSTRACT Cutaneous leishmaniasis is a neglected tropical disease with only one oral treatment option. DNDI‐6148 is an orally bioavailable compound with potent antiparasitic activity in preclinical studies. Establishing skin target‐site pharmacokinetic/pharmacodynamic (PK/PD) relationships is essential to enable its clinical development.
Rasmus Hansen Henninger, Wietse M. Schouten, Byron Arana, Jean‐Yves Gillon, Charles E. Mowbray, Jadel Müller Kratz, Katrien Van Bocxlaer, Thomas P. C. Dorlo   +7 more
wiley   +1 more source

Exploring Novel Nitrofuryl‐1,3,4‐Thiadiazole‐Based Derivatives: Design, Synthesis, and Evaluation of In Vitro Leishmanicidal and Trypanocidal Activity

Archiv der Pharmazie, Volume 359, Issue 3, March 2026.
In a series of substituted 1‐[5‐(5‐nitrofuran‐2‐yl)‐1,3,4‐thiadiazol‐2‐yl]piperidine‐4‐carboxamides evaluated for in vitro antileishmanial and antitrypanosomal activity, compound 18 emerged as the most promising derivative, showing submicromolar anti‐parasitic effects targeting diverse Leishmania and Trypanosoma species and acceptable selectivity ...
Alireza Mousavi, Martina Slapničková, Maryam Norouzbahari, Sarah D'Alessandro, Parham Foroumadi, Fariba Peytam, Federica Perego, Eva Doleželová, Zahra Emamgholipour, Maliheh Barazandeh Tehrani, Seyed Esmaeil Sadat‐Ebrahimi, Elahe Hosseinzadeh, Elmira Meghrazi Ahadi, Loghman Firoozpour, Hamidreza Bijanzadeh, Nicoletta Basilico, Alena Zíková, Alireza Foroumadi   +17 more
wiley   +1 more source

Combination of liposomal CpG oligodeoxynucleotide 2006 and miltefosine induces strong cell-mediated immunity during experimental visceral leishmaniasis. [PDF]

PLoS ONE, 2014
Immuno-modulators in combination with antileishmanial drug miltefosine is a better therapeutic approach for treatment of Visceral Leishmaniasis (VL) as it not only reduces the dose of miltefosine but also shortens the treatment regimen.
Rahul Shivahare, Preeti Vishwakarma, Naveen Parmar, Pawan Kumar Yadav, Wahajul Haq, Mrigank Srivastava, Suman Gupta, Susanta Kar   +7 more
doaj   +1 more source

Cutaneous Leishmaniasis in High‐Altitude: A Case Report From Nepal

Clinical Case Reports, Volume 14, Issue 3, March 2026.
ABSTRACT Leishmaniasis is a parasitic infection caused by Leishmania and spread by the bite of a sandfly, most commonly Phlebotomus. Among the three subtypes of Leishmaniasis, cutaneous leishmaniasis is the most common form. Visceral Leishmaniasis is common in Nepal whereas few cases of cutaneous leishmaniasis have been reported in migrant Nepalese ...
Eliz Aryal, Rohan Sapkota, Sunny Shrestha, Arika Baral, Santosh Sapkota, Mandish Prasad Phuyal   +5 more
wiley   +1 more source

A randomized, open-label clinical trial comparing the long-term effects of miltefosine and meglumine antimoniate for mucosal leishmaniasis

Revista da Sociedade Brasileira de Medicina Tropical, 2019
INTRODUCTION: The treatment of mucosal leishmaniasis (ML) is difficult due to the toxicity and route of administration of standard drugs. Miltefosine is an oral agent used for leishmaniasis treatment; however, no data exist regarding its use for ML in ...
Raimunda Nonata Ribeiro Sampaio, Juliana Saboia Fontenele e Silva, Carmen Dea Ribeiro de Paula, Cláudia Porto, Jorgeth de Oliveira Carneiro da Motta, Ledice Inacia de Araujo Pereira, Sofia Sales Martins, Daniel Holanda Barroso, Gustavo Subtil Magalhães Freire, Ciro Martins Gomes   +9 more
doaj   +1 more source

Monodentate Phosphine Modulation in Cyclometallated Platinum(II) Complexes for Antileishmanial, Antiviral, and Antitumor Applications

ChemMedChem, Volume 21, Issue 4, 25 February 2026.
Schematic representation depicting the influence of phosphine ligand identity on the biological and physicochemical characteristics of Pt(II) complexes: PTA promotes antileishmanial activity, PPh2(Php–COOH) strengthens antiviral activity, and TCEP enhances fluorescence.
Antonio A. de Oliveira‐Neto, Gustavo Clauss, Jennyfer Castro, Marcus S. A. Garcia, Natasha M. Cassani, Bruna C. Sandim, Ana Laura C. Oliveira, Stephanie P. B. Reyes, Nádija N. P. da Silva, Fillipe V. Rocha, Ana C. G. Jardim, Danilo C. Miguel, Camilla Abbehausen   +12 more
wiley   +1 more source